{"created_at":"Tue Oct 07 12:12:42 +0000 2014","id":519460305781669892,"id_str":"519460305781669892","text":"RT @BentheFidler: What Seattle Needs (Part 2): Dealing With Amgen\u2019s Upcoming Departure  http:\/\/t.co\/UuQfGzJ04u by Stewart Lyman $AMGN #biot\u2026","source":"\u003ca href=\"http:\/\/twitter.com\/download\/iphone\" rel=\"nofollow\"\u003eTwitter for iPhone\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":372270512,"id_str":"372270512","name":"Jonathan Mandelbaum","screen_name":"biotechbaumer","location":"Boston","url":"http:\/\/www.linkedin.com\/pub\/jonathan-mandelbaum\/5\/390\/919","description":"Biopharma drug discovery | Oncology | Classic Rock | Canadian-New Yorker hybrid | Tweets are my own opinion","protected":false,"verified":false,"followers_count":1098,"friends_count":157,"listed_count":69,"favourites_count":223,"statuses_count":2912,"created_at":"Mon Sep 12 13:26:06 +0000 2011","utc_offset":-18000,"time_zone":"Quito","geo_enabled":true,"lang":"en","contributors_enabled":false,"is_translator":false,"profile_background_color":"C0DEED","profile_background_image_url":"http:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_image_url_https":"https:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_tile":false,"profile_link_color":"0084B4","profile_sidebar_border_color":"000000","profile_sidebar_fill_color":"DDEEF6","profile_text_color":"333333","profile_use_background_image":true,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/1555316514\/profile_pic_compressed_normal.JPG","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/1555316514\/profile_pic_compressed_normal.JPG","default_profile":false,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweeted_status":{"created_at":"Tue Oct 07 11:17:21 +0000 2014","id":519446375897911296,"id_str":"519446375897911296","text":"What Seattle Needs (Part 2): Dealing With Amgen\u2019s Upcoming Departure  http:\/\/t.co\/UuQfGzJ04u by Stewart Lyman $AMGN #biotech","source":"\u003ca href=\"https:\/\/dev.twitter.com\/docs\/tfw\" rel=\"nofollow\"\u003eTwitter for Websites\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":1330055544,"id_str":"1330055544","name":"Ben Fidler","screen_name":"BentheFidler","location":"New York ","url":"http:\/\/xconomy.com\/author\/bfidler\/","description":"Deputy Biotechnology Editor, Xconomy.","protected":false,"verified":false,"followers_count":1257,"friends_count":186,"listed_count":52,"favourites_count":0,"statuses_count":755,"created_at":"Fri Apr 05 20:58:03 +0000 2013","utc_offset":null,"time_zone":null,"geo_enabled":false,"lang":"en","contributors_enabled":false,"is_translator":false,"profile_background_color":"C0DEED","profile_background_image_url":"http:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_image_url_https":"https:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_tile":false,"profile_link_color":"0084B4","profile_sidebar_border_color":"C0DEED","profile_sidebar_fill_color":"DDEEF6","profile_text_color":"333333","profile_use_background_image":true,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/378800000508787594\/1dddfdab18a8e169722db7beb3543eb7_normal.jpeg","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/378800000508787594\/1dddfdab18a8e169722db7beb3543eb7_normal.jpeg","default_profile":true,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweet_count":2,"favorite_count":0,"entities":{"hashtags":[{"text":"biotech","indices":[116,124]}],"trends":[],"urls":[{"url":"http:\/\/t.co\/UuQfGzJ04u","expanded_url":"http:\/\/www.xconomy.com\/seattle\/2014\/10\/07\/what-seattle-needs-part-2-dealing-with-amgens-upcoming-departure\/","display_url":"xconomy.com\/seattle\/2014\/1\u2026","indices":[70,92]}],"user_mentions":[],"symbols":[{"text":"AMGN","indices":[110,115]}]},"favorited":false,"retweeted":false,"possibly_sensitive":false,"filter_level":"low","lang":"en"},"retweet_count":0,"favorite_count":0,"entities":{"hashtags":[{"text":"biotech","indices":[134,140]}],"trends":[],"urls":[{"url":"http:\/\/t.co\/UuQfGzJ04u","expanded_url":"http:\/\/www.xconomy.com\/seattle\/2014\/10\/07\/what-seattle-needs-part-2-dealing-with-amgens-upcoming-departure\/","display_url":"xconomy.com\/seattle\/2014\/1\u2026","indices":[88,110]}],"user_mentions":[{"screen_name":"BentheFidler","name":"Ben Fidler","id":1330055544,"id_str":"1330055544","indices":[3,16]}],"symbols":[{"text":"AMGN","indices":[128,133]}]},"favorited":false,"retweeted":false,"possibly_sensitive":false,"filter_level":"medium","lang":"en","timestamp_ms":"1412683962685"}
